Raja Dhar India

Head of pulmonology at CK birla hospitals, kolkata and leading expert in respiratory medicine known for his leadership in clinical research and major medical conferences.
Job Title
Director, Department of Pulmonology
Faculty / Department / Division
Pulmonology
Institution / Organisation
Calcutta Medical Research Institute

21 November 2026, Saturday

Time Session
14:00
15:30
Chee-Shee Chai Chairperson Malaysia
Jung-Kyu Lee Chairperson Republic of Korea
  • Jin-Fu Xu Speaker China
  • Raja Dhar Speaker India
    COPD and bronchiectasis turn up together more often than chance would allow, and patients who have both do badly. In European and Indian cohorts the overlap carries about twice the mortality of either disease alone, along with more admissions and faster loss of lung function. The diagnosis is often made loosely; in the EMBARC registry, one in five patients labelled as COPD had no airflow obstruction. The ROSE criteria now give an objective definition and, importantly for us, accept biomass smoke as an exposure. Guidelines say little directly, so treatment is borrowed from both diseases. In India the overlap is commoner, often follows tuberculosis, and is still managed largely as COPD.
  • Tiew Pei Yee Speaker Singapore
    Chronic airway diseases including COPD, bronchiectasis, and bronchiectasis–COPD overlap (BCO) are biologically heterogeneous conditions. Advances in culture-independent sequencing have transformed our understanding of airway colonization, dysbiosis, and host–microbe interactions in these diseases. This presentation will provide an overview of the airway microbiome landscape across COPD, bronchiectasis, and BCO. I will discuss differences in microbial diversity, dominant pathogen patterns, and the concept of dysbiosis state. The talk will highlight how microbiome configurations relate to inflammation, exacerbation risk, and disease progression, and whether overlapping microbial signatures support shared biological mechanisms in BCO. Emerging approaches including longitudinal profiling, resistome and gut-lung axis will be discussed, with emphasis on how microbiome-informed stratification may guide precision therapy in chronic airway disease. This session aims to synthesize current evidence, identify knowledge gaps, and explore how airway microbiome research can be translated into clinically actionable strategies.
  • Q&A
Ballroom 2, Lower Ground Floor